Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation (IGI) Inc. has signed with Abbvie Inc. a global licensing partnership for trispecific antibody ISB-2001 worth $1.925 billion plus royalties. ISB-2001, which targets BCMA, CD38 and CD3, is in a phase I trial for relapsed/refractory multiple myeloma and has orphan drug and fast track status in the U.S Read More
It’s been more than seven years in coming, but the U.S. FDA is at last making public at least some of the complete response letters (CRLs) it’s sent to drug and biologic sponsors to notify them of deficiencies in their approval applications. Read More
Nuclidium AG is poised to circumvent the complex production and supply issues that have held back access to radiopharmaceuticals after closing a CHF79 million (US$99.3 million) series B, to advance the clinical development of its copper isotopes and extend the global manufacturing network. Read More
Ultragenyx Pharmaceutical Inc. and Mereo Biopharma Group plc, along with investors, had hoped for an early halt to the phase III study of setrusumab in treating brittle bones. They didn’t get it, as the clinical trial’s data monitoring committee wants the study to roll on through its final analysis. Read More
Historically, Q2 has often been one of the strongest quarters for biopharma financing, but 2025’s figures suggest a more cautious investment climate. Biopharma companies raised $16.02 billion in the second quarter (Q2) of 2025, a modest increase from the $13.11 billion brought during Q1. While the uptick signals some recovery from Q1, the sector is still pacing well behind the highs of recent years. Read More
Biopharmas raising money in public or private financings, including: Centivax, Cogent, Coregen, Galectin, Lixte, Oncozenge, Transposon, Zyversa. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biovie, Daiichi Sankyo, Kazia, Leol, Rhythm. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Eledon, Iambic, Jasper, Lupin, Novartis, Qanatpharma, Revolution Medicines, Sernova, Sironax, Zentiva. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adcentrx, Atsena, Connect, Eli Lilly, Iaso, Simcere, Trethera. Read More
